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Double-blind, placebo-controlled study of lurasidone
monotherapy for the treatment of bipolar I depression
Tadafumi Kato, MD, PhD ,1,2 Jun Ishigooka, MD, PhD,3 Mari Miyajima, PhD,4 Kei Watabe, MS,4
Tomohiro Fujimori, MS,4,5 Takahiro Masuda, PhD ,4* Teruhiko Higuchi, MD, PhD6,7 and Eduard Vieta, MD, PhD8
Aim: Previous studies conducted primarily in the USA and
Europe have demonstrated the efficacy and safety of
lurasidone 20–120 mg/day for the treatment of bipolar I
depression. The aim of the current study was to evaluate the
efficacy and safety of lurasidone monotherapy for the treat-
ment of bipolar I depression among patients from diverse
ethnic backgrounds, including those from Japan.
Methods: Patients were randomly assigned to double-blind
treatment for 6 weeks with lurasidone, 20–60 mg/day
(n = 184) or 80–120 mg/day (n = 169), or placebo (n = 172).
The primary end-point was change from baseline to Week
6 on the Montgomery–Åsberg Depression Rating Scale
(MADRS).
Results: Lurasidone treatment significantly reduced mean
MADRS total scores from baseline to Week 6 for the
20–60-mg/day group (−13.6; adjusted P = 0.007; effect
size = 0.33), but not for the 80–120-mg/day group (−12.6;
adjusted P = 0.057; effect size = 0.22) compared with
placebo (−10.6). Treatment with lurasidone 20–60 mg/day
also improved MADRS response rates, functional impair-
ment, and anxiety symptoms. The most common adverse
events associated with lurasidone were akathisia and nau-
sea. Lurasidone treatments were associated with minimal
changes in weight, lipids, and measures of glycemic control.
Conclusion: Monotherapy with once daily doses of
lurasidone 20–60 mg, but not 80–120 mg, significantly
reduced depressive symptoms and improved functioning in
patients with bipolar I depression. Results overall were con-
sistent with previous studies, suggesting that lurasidone
20–60 mg/day is effective and safe in diverse ethnic
populations, including Japanese.
Keywords: antipsychotic agents, bipolar disorder, depressive disor-
der, lurasidone hydrochloride.
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Bipolar disorder is a chronic psychiatric disorder with an estimated
lifetime prevalence worldwide ranging from 0.2% to 1.0%.1,2 It is
ranked among the top 20 causes of disability worldwide and among
the top 10 causes of disability in developed countries.3 The impair-
ment in social and occupational functioning due to bipolar disorder is
extensive. The impact on work functioning is observed in lost days
from work, loss of employment, and difficulty in regaining employ-
ment.4,5 The overall health-related quality of life found in individuals
with bipolar disorder is impaired to a level comparable with other
serious and chronic medical illnesses.6 Bipolar disorder has been
shown to reduce an individual’s expected life span by approximately
9 years.7 This is a result of a number of factors, including a higher
rate of comorbid medical conditions (such as obesity, diabetes, and
cardiovascular disease) and suicide.8–10 The annual economic burden
of bipolar disorder in the USA has been estimated to be about $31
billion in direct costs and an additional $120 billion in indirect
costs.11 In Japan, many individuals with bipolar disorder report a time
lag of many years before receiving an accurate diagnosis and also
report inability to work or study.12
Though episodes of mania or hypomania alternating with depres-
sive episodes are the traditional view of bipolar disorder, studies have
found that major depressive episodes are more common than manic
episodes over the course of the illness.13,14 However, treatment
options are limited for depressive episodes compared to manic epi-
sodes; for example, in Japan, olanzapine and quetiapine extended
release (XR) are the only approved treatments for bipolar depression
before the approval of lurasidone in 2020.15,16
Lurasidone is an atypical antipsychotic with high affinity for D2,
5-HT7, and 5-HT2A receptors (antagonist), moderate affinity for
5-HT1A receptor (partial agonist), and no clinically relevant affinity
for receptors such as histamine H1 and M1 receptors (IC50,
>1000 nM), or the 5-HT2C receptor (Ki, 415 nM).
17 Lurasidone
therefore shares the D2 and 5-HT2A antagonist characteristics of
second-generation antipsychotics that are hypothesized to contribute
to antipsychotic efficacy, with the 5-HT2A antagonism potentially
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limiting D2-antagonist-induced extrapyramidal adverse effects and
prolactin elevation. The high antagonist activity of lurasidone at the
5-HT7 receptor differentiates it from other second-generation antipsy-
chotics. This activity has been implicated in antidepressant like effect
in animal models.18 Consistent with this, lurasidone has demonstrated
efficacy in animal models of depression.19
The efficacy of lurasidone for the acute treatment of bipolar I
depression has been established in two 6-week randomized, double-
blind, placebo-controlled studies. These included studies of
lurasidone as a monotherapy20 and as an adjunctive therapy with lith-
ium or valproate.21 In both studies, lurasidone was found to reduce
primary measures of depressive symptoms to a significantly greater
degree than placebo with minimal changes in weight or metabolic
parameters. Lurasidone has been approved for bipolar I depression in
the USA and several other countries and is recommended as a first-
line treatment for bipolar I depression in international guidelines.22–24
Despite the two positive trials of lurasidone as a monotherapy or
adjunctive therapy for bipolar depression,20,21 the generalizability of
the results to diverse ethnic populations is not clear. Although both
trials were multicenter international studies, recruitment in these stud-
ies was limited to sites in the USA, Europe, and South Africa. Of
those randomized, 9.3% and 23.5% of the treatment samples were
from an Asian background in the monotherapy and adjunctive therapy
studies, respectively.
The goal of the current study was to further evaluate the efficacy
and safety of lurasidone as a monotherapy for bipolar I depression




This study enrolled male and female outpatients aged 18–74 years
who were currently experiencing a major depressive episode of at
least 4 weeks but less than 12 months in duration, and were diag-
nosed with bipolar I disorder, utilizing DSM-IV-TR criteria, and
including a history of at least one bipolar manic or mixed manic epi-
sode. A history of rapid cycling was permitted if episode frequency
in the 12 months prior to screening was ≥4 episodes but <8 episodes.
Diagnosis was determined using the Mini-International Neuropsychi-
atric Interview.25 To be included, patients also needed to have a
Montgomery–Åsberg Depression Rating Scale (MADRS)26
score ≥ 20 and a Young Mania Rating Scale (YMRS)27 score ≤ 12 at
both screening and baseline.
Patients were excluded if they had current psychotic features
(a past history was not exclusionary) or had another Axis I or Axis II
disorder other than bipolar disorder that was the focus of treatment
received in the 3 months prior to screening. Also excluded were
patients: who scored ≥4 on MADRS Item 10 (suicidal thoughts) at
screening or baseline; who had a history of nonresponse to an ade-
quate (6-week) trial of three or more antidepressants (with or without
mood stabilizers) during the current depressive episode; who had
been hospitalized for a manic or mixed episode within 60 days of
screening; and who responded Yes to the Columbia Suicide Severity
Rating Scale (C-SSRS)28 Item 4 (active suicidal ideation with some
intent to act, without specific plan) or Item 5 (active suicidal ideation
with specific plan and intent) at screening (within 6 months prior to
screening) or at baseline, or were otherwise judged to be an imminent
risk of suicide or injury to self, others, or property.
An institutional review board at each investigational site
reviewed and approved the study. The study was conducted in accor-
dance with the International Conference on Harmonization Good
Clinical Practices guidelines and with the ethical principles of the
Declaration of Helsinki. Prior to enrollment, all patients reviewed and
signed an informed consent document explaining study procedures
and potential risks and authorizing publication. The study was moni-
tored by an independent data and safety monitoring board throughout
the study.
Study design
This study was a randomized, double-blind, placebo-controlled,
flexible-dose, parallel-group, monotherapy study of lurasidone.
Patients were enrolled at 102 centers in eight countries. This included
55 centers in Japan, three centers in Lithuania, five centers in Malay-
sia, three centers in the Philippines, 19 centers in Russia, five centers
in Slovakia, three centers in Taiwan, and nine centers in the Ukraine.
The study was conducted from February 2014 to February 2017.
Following a washout period of 3 or more days (as needed),
patients were randomly assigned in a 1:1:1 ratio via an interactive
web response system to receive 6 weeks of lurasidone 20–60 mg/day
(flexibly dosed), lurasidone 80–120 mg/day (flexibly dosed), or pla-
cebo. Study medication was provided in blister packs as either
lurasidone 20 mg or identically matched placebo tablets. Lurasidone
dosing was fixed at 20 mg/day for Days 1 to 7 in the 20–60-mg/day
treatment arm. Patients randomized to the lurasidone 80–120-mg/day
treatment arm were to receive 20 mg/day on Days 1 and 2, 40 mg/day
on Days 3 and 4, 60 mg/day on Days 5 and 6, and 80 mg/day on Day
7. Thereafter, in both lurasidone groups, lurasidone was to be flexibly
dosed starting on Day 8. At the scheduled visits at Week 1 or after,
when no safety concerns were found and the Clinical Global Impres-
sion: Bipolar Version – Severity of Illness (CGI-BP-S29) Depression
score was within the range of 5 (markedly ill) to 7 (very severely ill),
the dose was to be increased by 20 mg/day. If any safety concerns
were evident, the dose could be reduced by 20 mg/day at an
unscheduled visit. Lurasidone (or placebo) was taken once daily,
within 30 min after the evening meal.
Concomitant medications
During the treatment period, lorazepam (≤2 mg/day) was permitted as
needed for the treatment of anxiety, agitation, irritability, and related
psychiatric symptoms, between screening and Week 3. Hypnotics
were permitted between screening and Week 3 for insomnia. All other
psychotropic medications were prohibited for the full treatment
period. Other medications prohibited during the study were known
CYP3A4 inhibitors and inducers as well as Chinese herbal medica-
tions. For patients treated with antiparkinson agents at screening, the
medications were to be titrated down appropriately and terminated
before the initiation of the study treatment. For all patients, if any
extrapyramidal symptoms developed or worsened after the initiation
of the study treatment, permitted antiparkinson medications included
biperiden (≤16 mg), trihexyphenidyl (≤10 mg), benztropine (≤6 mg),
and diphenhydramine (≤300 mg). For akathisia, propranolol
(≤120 mg/day), amantadine (≤300 mg/day), or one of the allowable
antiparkinson medications was permitted.
Efficacy assessments
The primary efficacy end-point was the mean change in the MADRS
total score (range: 0–60) from baseline to Week 6. Certified raters
conducted the MADRS assessment at each visit. Secondary efficacy
assessments included the CGI-BP-S Depression score (range: 1–7),
the Sheehan Disability Scale (SDS)30 total score (range: 0–30), the
Hamilton Anxiety Rating Scale (HAM-A31; range: 0–56), the YMRS
(range: 0–60), MADRS response and remission rates, and time to
response. The MADRS, CGI-BP-S, and YMRS were obtained at
baseline and every week for 6 weeks; the HAM-A and SDS were
obtained at baseline and Week 6. Response was defined as a ≥50%
reduction from baseline in the MADRS total score at Week 6; remis-
sion was defined as an MADRS total score of ≤12 at Week 6. Explor-
atory post-hoc efficacy analysis was also conducted on the individual
MADRS item scores and the MADRS-6 subscale,32 which evaluates
the ‘core depressive symptoms’ (as assessed by the MADRS items:
apparent sadness, reported sadness, inner tension, lassitude, inability
to feel, and pessimistic thoughts).
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Safety and tolerability evaluations
Safety and tolerability were assessed throughout the study by: the
incidence and severity of treatment-emergent adverse events
(TEAEs); laboratory measures of prolactin, glucose metabolism, and
lipid metabolism; vital signs; weight; and QTc interval determined
from electrocardiography (ECG) measurements. In addition, the influ-
ence of treatment on extrapyramidal symptoms was evaluated, as
evidenced by extrapyramidal adverse events, proportion of patients
using concomitant antiparkinson drugs, and changes on the Drug-
Induced Extrapyramidal Symptoms Scale (DIEPSS).33 Treatment-
emergent mania was defined as a YMRS total score of ≥16 at any
two consecutive post-baseline visits, or at the final assessment, or any
TEAEs related to mania symptoms. Suicidal ideation and behavior
were evaluated with the C-SSRS.
Statistical analysis
The intent-to-treat population consisted of randomly assigned patients
who received at least one dose of study medication and had baseline
and at least one post-baseline MADRS total score. A mixed-effects
model for repeated measures (MMRM) was used to analyze the pri-
mary efficacy variable (the change from baseline in MADRS total
score at Week 6). The MMRM method included treatment, visit,
pooled center, baseline MADRS total score, and treatment-by-visit
interaction. An unstructured covariance matrix was used for the
within-patient correlation. For the primary efficacy variable, P-values
were adjusted for multiplicity (comparisons of each of the lurasidone
groups to placebo) using a Hochberg procedure. The individual
MADRS item scores, the MADRS-6 subscale, and CGI-BP-S score
were also analyzed using the MMRM approach. Effect sizes at Week
6 were calculated as the absolute value of the least square (LS) mean
difference from placebo divided by the model estimate of the standard
deviation (SD), with both the LS mean and estimated SD obtained
from the MMRM analysis. Additional secondary efficacy measures
(SDS, HAM-A, YMRS) were examined using an analysis of covari-
ance (ANCOVA) model. The ANCOVA model included treatment as
a categorical factor, pooled center, and the score on the efficacy mea-
sure at baseline as a covariate. The response variable for the model
was the change from baseline in the efficacy measure at Week 6 using
last observation carried forward (LOCF). Logistic regression was
used to evaluate the proportions of patients achieving both treatment
response and symptom remission. For these analyses, predictor vari-
ables included treatment group, pooled study site, and the MADRS
total score at baseline, all entered using the forced-entry method.
Number needed to treat (NNT) was calculated as the reciprocal of the
difference in the proportion of responders in the lurasidone group and
the proportion of responders in the placebo group. For time-to-
response analysis, patients failing to achieve MADRS response were
censored. Kaplan–Meier plots were displayed, and a log–rank test and
a Cox regression model analysis were used for comparing the treat-
ment groups.
The population for safety analyses included all patients who
were randomized and received at least one dose of study medication.
MMRM analyses were used to examine treatment group differences
in the change from baseline in the DIEPSS total score (excluding
overall severity; range: 0–32). The numbers and percentages of
patients with TEAEs, treatment-emergent mania, and concomitant use
of antiparkinson medication were summarized by treatment groups.
Relevant summary statistics for laboratory tests, vital signs,
bodyweights, and 12-lead ECG parameters were calculated by treat-
ment group. A rank ANCOVA method with adjustments for baseline
values was applied to change from baseline to Week 6 (LOCF) in
serum prolactin, blood glucose, HbA1c (National Glycohemoglobin
Standardization Program), total cholesterol, LDL cholesterol, HDL
cholesterol, triglycerides, weight, and body mass index for compari-
son between each lurasidone group and the placebo group. There was
no multiplicity adjustment for the secondary efficacy analyses or
safety analyses.
Sample size for the primary efficacy analysis was determined by
a Monte-Carlo simulation using SAS Version 9.2 (SAS Institute,
Cary, NC, USA). A common effect size of 0.35 (i.e., an intergroup
difference in change from baseline of 3.5 with an SD of 10) in the
MADRS total score for both lurasidone groups over the placebo
group was used for estimating the sample size. This resulted in a sam-
ple size of 161 per group for a total of 483 patients to yield power
(probability of rejecting two null hypotheses) of 80%, with a 1-sided
2.5% significance level using Hochberg procedure for multiplicity
adjustment. To account for attrition (patients randomized who provide
no post-baseline MADRS total scores), the sample size was planned
to be 501 patients or 167 patients per treatment group. The conserva-
tive estimate for assumed effect size 0.35 was made because of the
limited number of placebo-controlled clinical studies in patients with
depressive symptoms associated with bipolar disorder in Japan or
Asia where a portion of the current sample was recruited.
Results
Patients and disposition
A total of 624 patients were screened for the study; 525 were ran-
domly assigned to 6 weeks of double-blind treatment (Fig. 1) and all
of these received at least one dose of study medication (safety popula-
tion). Three patients were excluded from the intent-to-treat population
because of lack of at least one post-baseline MADRS total score,
resulting in an analysis sample of 182 patients in the lurasidone
20–60-mg/day group, 169 in the lurasidone 80–120-mg/day group,
and 171 in the placebo group. Baseline demographic and clinical
characteristics were similar among the three treatment groups
(Table 1). There were 178 patients (34.1% of the study population)
who received treatment in Japan. Study completion rates were 85.3%
for the lurasidone 20–60-mg/day group, 81.1% for the lurasidone
80–120-mg/day group, and 80.8% for the placebo group (Fig. 1).
The mean (SD) daily dose of lurasidone during the study was
36.2  12.0 mg in the 20–60-mg/day group and 85.4  14.2 mg in
the 80–120-mg/day group. In the 20–60-mg/day group, the percent of
patients utilizing a modal dose of 20 mg, 40 mg, and 60 mg was
36.8%, 23.1%, and 40.1%, respectively. In the 80–120-mg/day group,
the percent of patients utilizing a modal dose of 80 mg, 100 mg, and
120 mg was 41.4%, 26.0%, and 30.2%, respectively. Use of loraze-
pam as needed was reported for 15.8% of patients in the lurasidone
20–60-mg/day group, 17.2% in the lurasidone 80–120-mg/day group,
and 18.0% in the placebo group. Use of hypnotics as needed was
reported for 24.5% of patients in the lurasidone 20–60-mg/day group,
26.6% in the lurasidone 80–120-mg/day group, and 28.5% in the pla-
cebo group.
Efficacy
On the primary end-point, the lurasidone 20–60-mg/day group, but
not the lurasidone 80–120-mg/day group, was significantly supe-
rior to placebo. The LS mean change (SE) in the MADRS total
score from baseline to Week 6 was −13.6  0.69 (adjusted
P = 0.007; effect size = 0.33 vs placebo) for the lurasidone
20–60-mg/day group, −12.6  0.73 (adjusted P = 0.057; effect
size = 0.22 vs placebo) for the lurasidone 80–120-mg/day group,
and −10.6  0.72 for the placebo group (Fig. 2a). In the
80–120-mg/day group, effect sizes for modal daily lurasidone
doses of 80 mg, 100 mg, and 120 mg were 0.34, 0.27, and 0.06,
respectively, based on a post-hoc analysis. In the lurasidone
20–60-mg/day group, superiority compared with placebo on the
MADRS was observed from Week 2 through to Week 6 (Fig. 2a).
Both lurasidone treatment groups showed significantly greater
improvement from baseline to Week 6 compared with placebo in
core depressive symptoms (MADRS-6 subscale score; Table S1).
The proportion of patients with a response on the MADRS total
score was significantly greater (P = 0.003) in the lurasidone
20–60-mg/day group (84 patients, 46.2% [NNT = 7]) but not in the
lurasidone 80–120-mg/day group (65 patients, 38.5%; P = 0.145)
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compared with the placebo group (31.0%). Remission was achieved
by 31.9% of those in the lurasidone 20–60-mg/day group (P = 0.064
vs placebo), 29.0% of those in the lurasidone 80–120-mg/day group
(P = 0.172 vs placebo), and 22.8% of those in the placebo group.
Results for the time-to-response analyses based on a Kaplan–Meier
estimate showed a probability of response by Week 6 (up to Day 42)
of 53.1% for the lurasidone 20–60-mg/day group (P = 0.02 vs pla-
cebo), 51.6% for the lurasidone 80–120-mg/day group (P = 0.054 vs
placebo), and 39.3% for the placebo group. The Cox proportional
hazard ratio of MADRS response was significantly higher for the
lurasidone 20–60-mg/day group (1.5; 95% confidence interval [CI],
1.1–2.1; P = 0.010) and for the lurasidone 80–120-mg/day group
(1.5; 95%CI, 1.0–2.0; P = 0.025) compared with the placebo group.
Improvement in the CGI-BP-S Depression score from baseline
to Week 6 was significantly different for both lurasidone treatment
groups compared with placebo (MMRM). The LS mean change
(SE) from baseline to Week 6 was −1.51  0.09 (P = 0.002; effect
size = 0.35 vs placebo) for the lurasidone 20–60-mg/day group,
−1.41  0.09 (P = 0.019; effect size = 0.27 vs placebo) for the
lurasidone 80–120-mg/day group, and −1.11  0.09 for the placebo
group (Fig. 2b). For both dosages of lurasidone, significantly greater
reduction compared with placebo on the CGI-BP-S Depression score
was observed starting at Week 3 and this was maintained at all subse-
quent study visits.
Treatment with lurasidone 20–60 mg/day was associated with
significant improvement from baseline to Week 6 compared with pla-
cebo in functioning, as measured by the patient-rated SDS, and in
anxiety symptoms, as measured by the HAM-A (Table 2). No
significant differences were evident comparing the lurasidone
80–120-mg/day group to placebo on the HAM-A or SDS. The YMRS
total scores were slightly decreased from baseline at Week 6 in all
groups despite the low baseline score (Table 2).
Safety
Overall, treatment with lurasidone 20–60 mg/day and 80–120 mg/day
was safe and well tolerated. TEAEs were reported by 53.3% of
patients in the lurasidone 20–60-mg/day group, 59.2% of patients in
the lurasidone 80–120-mg/day group, and 45.9% of patients in the
placebo group. The majority of TEAEs reported were classified as
either mild or moderate in severity. Severe TEAEs were reported for
three patients (1.6%) in the lurasidone 20–60-mg/day group, nine
patients (5.3%) in the lurasidone 80–120-mg/day group, and two
patients (1.2%) in the placebo group.
Serious adverse events during treatment were reported for two
patients (1.1%) in the lurasidone 20–60-mg/day group, four patients
(2.4%) in the lurasidone 80–120-mg/day group, and five patients
(2.9%) in the placebo group. Treatment discontinuation due to a
TEAEs was reported for six patients (3.3%) in the lurasidone
20–60-mg/day group, 16 patients (9.5%) in the lurasidone
80–120-mg/day group, and seven patients (4.1%) in the placebo
group. There were no treatment-emergent deaths reported during the
6-week treatment phase of the study.
The most common TEAEs were akathisia, nausea, and somno-
lence (Table 3). These TEAEs (akathisia, nausea, somnolence) were
more frequent in the lurasidone 80–120-mg/day group (23.7%,
Assessed for eligibility (n = 624)
Randomized (n = 525)
Lurasidone 20–60 mg/day (n = 184) Lurasidone 80–120 mg/day (n = 169) Placebo (n = 172)
Received intervention (n = 184)
Completers (n = 157) 
Discontinued intervention (n = 27)
Adverse event (n = 6)
Lack of efficacy (n = 6)
Withdrew consent (n = 13)
Lost to follow-up (n = 1)
Study drug non-compliance (n = 1)
Intent-to-treat population (n = 182)
Safety analysis population (n = 184)
Intent-to-treat population (n = 169)
Safety analysis population (n = 169)
Intent-to-treat population (n = 171)
Safety analysis population (n = 172)
Protocol violation (n = 0)
Discontinued intervention (n = 32)
Adverse event (n = 16)
Lack of efficacy (n = 11)
Withdrew consent (n = 5)
Lost to follow-up (n = 0)
Study drug non-compliance (n = 0)
Protocol violation (n = 0)
Discontinued intervention (n = 33)
Adverse event (n = 7)
Lack of efficacy (n = 8)
Withdrew consent (n = 14)
Lost to follow-up (n = 1)
Study drug non-compliance (n = 0)
Protocol violation (n = 0)
Completers (n = 137) Completers (n = 139)
Received intervention (n = 169) Received intervention (n = 172)
Excluded (n = 99)
Other (n = 0) Other (n = 0) Other (n = 3)
Fig.1 Patient disposition.
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11.8%, 6.5%, respectively) compared to the 20–60-mg/day group
(13.0%, 6.5%, 3.8%, respectively). Other common TEAEs in the
lurasidone groups with a rate greater than in the placebo group were
parkinsonism and nasopharyngitis (Table 3). All but two cases of
akathisia were reported as mild or moderate in severity. Nausea was
the only TEAEs leading to discontinuation in more than 2% of
patients in a group (2.4% in the lurasidone 80–120-mg/day group).
Treatment-emergent mania occurred in seven patients (3.8%) in
the lurasidone 20–60-mg/day group, three patients (1.8%) in the
lurasidone 80–120-mg/day group, and four patients (2.3%) in the pla-
cebo group. Odds ratios for developing treatment-emergent mania
compared with placebo were 2.3 (95%CI, 0.4–12.4; P = 0.334) for
the lurasidone 20–60-mg/day group and 1.1 (95%CI, 0.1–8.1;
P = 0.939) for the lurasidone 80–120-mg/day group. Based on the C-
SSRS, there was no notable difference in the proportion of patients
with at least one post-baseline instance of suicidality (defined as sui-
cidal ideation or behavior) comparing the lurasidone 20–60-mg/day
group (27 patients, 14.8%) and the lurasidone 80–120-mg/day group
(24 patients, 14.2%) with the placebo group (27 patients, 15.8%).
Emergence of suicidal behavior after baseline was reported for one
patient (0.5%) in the lurasidone 20–60-mg/day group, one patient
(0.6%) in the lurasidone 80–120-mg/day group, and no patients in the
placebo group.
TEAEs related to extrapyramidal symptoms were reported for
eight patients (4.3%) in the lurasidone 20–60-mg/day group,
18 patients (10.7%) in the lurasidone 80–120-mg/day group, and
11 patients (6.4%) in the placebo group. There were no significant
differences between the DIEPSS total scores for the lurasidone
20–60-mg/day group and the placebo group at any of the study visits.
There was a significant difference between the lurasidone 80–120-mg/
day group and the placebo group for change from baseline to Week
6 in the DIEPSS total score. However, mean change (SE) in total
score from baseline to Week 6 was very small in all groups (Table 2).
One or more concomitant antiparkinson medications was recorded for
6.0% of patients in the lurasidone 20–60-mg/day group, 20.7% of
patients in the lurasidone 80–120-mg/day group, and 3.5% of patients
in the placebo group.
Metabolic-related TEAEs were reported for five patients (2.7%)
in the lurasidone 20–60-mg/day group, one patient (0.6%) in the
lurasidone 80–120-mg/day group, and four patients (2.3%) in the pla-
cebo group. There were no clinically relevant changes from baseline
to Week 6 (LOCF) in metabolic parameters in patients receiving
lurasidone (either dose) compared with patients receiving placebo
(Table 4).
Prolactin concentrations from baseline to Week 6 (LOCF) were
increased in the lurasidone 20–60-mg/day group and in the lurasidone
80–120-mg/day group relative to the placebo group (P < 0.01 for both
groups; Table 4). Markedly abnormal post-baseline change in prolac-
tin (≥5-fold of upper limit of normal) occurred in 1.1% (two patients)
in the lurasidone 20–60-mg/day group, 0.6% (one patient) in the
lurasidone 80–120-mg/day group, and no patients in the placebo
group. There was no evidence of toxicity as measured by clinical
Table 1. Baseline characteristics (intent-to-treat population)
Lurasidone Lurasidone Placebo
20–60 mg/day 80–120 mg/day
(n = 182) (n = 169) (n = 171)
Demographics and clinical characteristics
Female sex, n (%) 95 (52.2%) 88 (52.1%) 94 (55.0%)
Age (years), mean (SD) 42.6 (12.9) 43.2 (12.8) 41.3 (12.6)
Race, n (%)
White 105 (57.7%) 103 (60.9%) 94 (55.0%)
Asian 77 (42.3%) 66 (39.1%) 77 (45.0%)
Country, n (%)
Japan 65 (35.7%) 53 (31.4%) 60 (35.1%)
Malaysia 6 (3.3%) 6 (3.6%) 7 (4.1%)
Philippines 3 (1.6%) 3 (1.8%) 5 (2.9%)
Russia 51 (28.0%) 50 (29.6%) 44 (25.7%)
Taiwan 3 (1.6%) 4 (2.4%) 5 (2.9%)
Ukraine 43 (23.6%) 45 (26.6%) 43 (25.1%)
Lithuania 4 (2.2%) 4 (2.4%) 2 (1.2%)
Slovakia 7 (3.8%) 4 (2.4%) 5 (2.9%)
Duration of bipolar I disorder (years), mean (SD) 12.1 (10.5) 12.4 (10.7) 12.1 (9.7)
With rapid cycling, n (%) 19 (10.4%) 19 (11.2%) 16 (9.4%)
Efficacy measures
MADRS total score, mean (SD) 30.6 (5.6) 30.8 (5.1) 30.9 (5.4)
CGI-BP-S Depression score, mean (SD) 4.57 (0.70) 4.58 (0.60) 4.60 (0.69)
SDS total score,† mean (SD) 29.4 (5.3) 19.8 (5.6) 19.9 (5.2)
HAM-A total score, mean (SD) 17.6 (7.2) 16.7 (6.2) 17.1 (6.6)
YMRS total score, mean (SD) 2.92 (2.49) 2.67 (2.29) 2.62 (2.23)
Safety measure
DIEPSS total score (excluding overall severity), mean (SD) 0.41 (1.01) 0.39 (0.83) 0.36 (0.93)
†Number of patients: lurasidone 20–60 mg/day = 154; lurasidone 80–120 mg/day = 127; placebo = 141.
CGI-BP-S, Clinical Global Impression, Bipolar Version -Severity of Illness; DIEPSS, Drug-Induced Extrapyramidal Symptoms Scale; HAM-A,
Hamilton Anxiety Rating Scale; MADRS, Montgomery–Åsberg Depression Rating Scale; SDS, Sheehan Disability Scale; YMRS, Young Mania
Rating Scale.
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Table 2. Secondary efficacy and safety measures: Least square mean change (SE) from baseline to Week 6 (intent-to-treat population)














Efficacy measure (LOCF, ANCOVA)
SDS 147 19.4 (5.3) −7.6 (0.6)* 124 19.8 (5.6) −6.8 (0.7) 128 20.3 (5.0) −5.7 (0.7)
HAM-A 179 17.6 (7.3) −7.4 (0.5)* 167 16.7 (6.2) −6.4 (0.5) 164 17.2 (6.6) −5.7 (0.5)
YMRS 182 2.92 (2.49) −0.64 (0.22) 169 2.67 (2.29) −0.87 (0.23)* 171 2.62 (2.23) −0.22 (0.23)
Safety measure (MMRM)
DIEPSS 182 0.41 (1.01) −0.01 (0.08) 169 0.39 (0.83) 0.39 (0.09)** 171 0.36 (0.93) −0.02 (0.09)
*P < 0.05; **P < 0.01, comparisons to placebo group.
ANCOVA, analyses of covariance; DIEPSS, Drug-Induced Extrapyramidal Symptoms Scale total score (excluding severity); HAM-A, Hamilton
Anxiety Rating Scale total score; LOCF, last observation carried forward; MMRM, mixed-effects model for repeated measures; SDS, Sheehan

















Change from baseline in MADRS total score (MMRM) – ITT population(a)















































































Week 1 Week 2 Week 3 Week 4 Week 5 Week 6
Baseline Week 1 Week 2 Week 3 Week 4 Week 5 Week 6
Fig.2 (a) Change from baseline in Montgomery–Åsberg
Depression Rating Scale (MADRS) total score (mixed-effects
model for repeated measures [MMRM]) – intent-to-treat (ITT)
population. *P < 0.05, **P < 0.01, ***P < 0.001 (vs pla-
cebo). Adjustments for multiple comparisons by Hochberg
(only at Week 6) , Placebo (n = 171); , Lurasidone
20–60 mg/day (n = 182); , Lurasidone 80–120 mg/day
(n = 169). (b) Change from baseline in Clinical Global
Impression: Bipolar Version – Severity of Illness (CGI-BP-S)
Depression score (MMRM) – ITT population. *P < 0.05,
**P < 0.01, ***P < 0.001 (vs placebo). No adjustments for
multiple comparisons , Placebo (n = 171); ,
Lurasidone 20–60 mg/day (n = 182); , Lurasidone 80–
120 mg/day (n = 169).
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laboratory, hematological, and urinalysis parameters of lurasidone-
treated patients compared with placebo-treated patients.
Analysis of vital signs and physical findings did not reveal any
clinically relevant effect of lurasidone treatment in the full sample.
There was no effect of lurasidone when compared with placebo on
pulse rate, blood pressure (systolic or diastolic), or body temperature.
There were no clinically relevant effects on weight or body mass
index (Table 4). The proportions of patients with ≥7% weight
increase/decrease were 1.1%/1.1%, 1.2%/0.6%, and 0%/0% in the
lurasidone 20–60-mg/day group, the lurasidone 80–120-mg/day
group, and the placebo group, respectively. There were no clinically
relevant changes from baseline to Week 6 in ECG parameters in any
of the treatment groups.
Discussion
This 6-week, multicenter, international study found that monotherapy
with lurasidone (20–60 mg/day) for bipolar I depression was signifi-
cantly superior to placebo in reducing depressive symptoms as mea-
sured by the MADRS total score (primary end-point), with
improvement evident as early as Week 2. Significantly greater
improvement for the lurasidone 20–60-mg/day group, compared to
placebo, was also evident on the following secondary measures at
Week 6: responder rates, Kaplan–Meier estimate of the probability of
response, improvement in global illness severity (CGI-BP-S Depres-
sion score), reduction in anxiety symptoms (HAM-A), and improve-
ment in patient-rated functioning (on the SDS).
A meta-analysis of placebo-controlled, monotherapy trials of
mood-stabilizing anticonvulsants, second-generation antipsychotics,
and lithium for bipolar depression reported an overall NNT of 8.2 for
a comparison of responder rates versus placebo.34 The NNT value of
lurasidone 20–60 mg/day was 7 and in the same range as reported in
the meta-analysis, suggesting clinical significance. The efficacy pro-
file of lurasidone 20–60 mg/day is consistent with the previous study
of lurasidone as monotherapy for bipolar I depression conducted
mainly in the USA and Europe,20 suggesting that lurasidone has
broad efficacy across various ethnic populations.
In the previous monotherapy study,20 lurasidone 80–120 mg/day
significantly reduced depressive symptoms compared to placebo on
the primary end-point. However, in the current study the higher
(80–120 mg/day) dose range of lurasidone did not demonstrate signif-
icant improvement on the MADRS (adjusted P = 0.057).
In the current study, the modal daily dose used by 30.2% of the
patients in the lurasidone 80–120-mg/day dosage group was the maxi-
mum dose of 120 mg, which was almost two-fold higher than the rate
reported in the previous monotherapy study (16.1%).20 This may be
partly attributable to dose escalation criteria added in the current pro-
tocol that encouraged continued dose increases until depression sever-
ity was reduced (CGI-BP-S Depression score ≤ 4). Patients treated
with higher doses may achieve higher plasma concentrations of
lurasidone, which in turn have been correlated with notably higher
dopamine D2 receptor occupancy levels.35 It has been suggested that
high levels of D2 receptor occupancy may be associated with dyspho-
ria.36 In the current study, the lower effect size observed on the modal
daily dose of 120 mg of lurasidone may be attributable to this D2
receptor occupancy effect, and this may be associated with reduced
efficacy in the high-dose group.
The safety profile for lurasidone in the current study was compa-
rable to that reported in previous trials. The most common TEAEs
was akathisia, which occurred with a higher frequency in the current
study (vs the previous monotherapy study20) both in the 20–60-mg/
Table 3. Treatment-emergent adverse events (safety population;
n [%])
Lurasidone Lurasidone Placebo
20–60 mg/day 80–120 mg/day
(n = 184) (n = 169) (n = 172)
At least one event 98 (53.3%) 100 (59.2%) 79 (45.9%)
Event (incidence ≥ 5%)
Akathisia 24 (13.0%) 40 (23.7%) 11 (6.4%)
Nausea 12 (6.5%) 20 (11.8%) 10 (5.8%)
Somnolence 7 (3.8%) 11 (6.5%) 7 (4.1%)
Nasopharyngitis 10 (5.4%) 6 (3.6%) 8 (4.7%)
Headache 5 (2.7%) 9 (5.3%) 15 (8.7%)
Parkinsonism 4 (2.2%) 10 (5.9%) 4 (2.3%)
Table 4. Baseline and mean change to Week 6 (LOCF) in laboratory parameters (safety population)




















Total cholesterol (mg/dl)† 164 205.2 (44.3) −5.6 (28.9) 0.0 151 199.8 (40.9) −4.2 (35.1) −7.0 158 201.9 (44.4) −4.6 (28.2) −4.5
LDL cholesterol (mg/dL)† 160 122.0 (38.8) −4.7 (26.6) −4.0 145 118.4 (38.1) −3.1 (28) −4.0 152 118.2 (38.0) −3.5 (24.3) −2.5
Triglycerides (mg/dL)† 164 142.8 (93.3) −7.9 (74.5) −6.0 151 138.4 (86.3) 8.8 (128.1) −2.0 158 131.1 (95.3) −0.8 (68.8) 0.5
Glucose (mg/dL)† 163 96.2 (13.8) −1.1 (13.9) −2.0 151 96.7 (14.3) 0.3* (12.7) 1.0 159 97.1 (14.7) −2.9 (13.1) −2.0
HbA1c (%) 174 5.32 (0.41) 0.01 (0.21) 0.00 164 5.30 (0.43) 0.02* (0.25) 0.00 164 5.29 (0.39) −0.02 (0.22) 0.00
Insulin (mU/L)† 173 13.1 (13.1) 0.4 (18.6) −0.1 157 12.9 (10.4) 2.8 (13.2) −0.2 163 15.2 (17.5) −1.5 (19.1) −0.3
Prolactin (ng/mL), overall 176 9.9 (11.6) 3.5** (17.0) 1.8 167 14.2 (28.8) 4.3** (18.9) 2.8 165 13.2 (19.7) −1.5 (20.3) 0.0
Prolactin (ng/mL), male 83 7.3 (6.3) 1.9** (7.8) 1.2 79 8.8 (10.7) 2.4** (13.3) 2.7 75 10.5 (11.6) −3.0 (10.3) −0.4
Prolactin (ng/mL), female 93 12.3 (14.5) 5.0** (22.1) 2.6 88 19.1 (37.9) 6.1** (22.8) 3.5 90 15.5 (24.3) −0.4 (25.9) 0.5
Weight (kg) 179 72.0 (13.7) 0.16** (1.85) 0.2 166 73.9 (16.8) 0.0 (2.03) 0.0 166 71.3 (14.3) −0.29 (1.49) −0.1
Body mass index (kg/m2) 179 25.6 (4.1) 0.07** (0.66) 0.07 166 26.1 (5.0) 0.0 (0.71) 0.00 166 25.3 (4.3) −0.1 (0.54) −0.03
†Fasting condition.
*P < 0.05; **P < 0.01, comparisons to placebo group.
LOCF, last observation carried forward.
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day group (13.0% vs 7.9%), and in the 80–120-mg/day group (23.7%
vs 10.8%). It is notable that the rate of akathisia reported in the pla-
cebo group was also higher in the current study (vs the previous mon-
otherapy study: 6.4% vs 2.4%), resulting in similar placebo-adjusted
rates for both studies. Consistent with this, in the current study, no
patients in the lurasidone 20–60-mg/day group reported severe
akathisia, and rates of treatment discontinuation due to akathisia were
low and similar to placebo (0.6% vs 0.5%). Among patients in the
lurasidone 80–120-mg/day group, two reported severe akathisia and
discontinuation due to akathisia was 1.8%. Treatment discontinuation
due to any TEAEs was also low in the lurasidone 20–60-mg/day
group and comparable to placebo (3.3% vs 4.1%), and was somewhat
higher in the 80–120-mg/day group (9.5%).
In comparing lurasidone dose groups to placebo, there were no
differences in rates of treatment-emergent mania. This is notable
given the risk of treatment-emergent mania that has been reported
when using antidepressants in the treatment of bipolar depression.37
YMRS scores were low at baseline and remained unchanged after
6 weeks of treatment with both doses of lurasidone. Previous studies
indicate that long-term treatment with lurasidone in bipolar depres-
sion is associated with a low risk of triggering a manic switch; and in
one double-blind maintenance trial in bipolar depression, lurasidone
was associated with a 43% reduction in the risk of developing mania
versus placebo (both treatment groups utilized adjunctive lithium or
valproate).38,39 Many antipsychotics have demonstrated efficacy in
treatment of acute manic and mixed manic episodes; however, ran-
domized trials of lurasidone have not been reported.40
The results of the current study found lurasidone to have mini-
mal effects on weight and metabolic parameters. Multiple studies of
lurasidone in patients with both bipolar disorder and schizophrenia
have reported similar findings.39,41,42 As bipolar disorder is associated
with high rates of metabolic syndrome and cardiovascular
mortality,43,44 the favorable metabolic profile of lurasidone is an
important safety consideration, especially given the frequent need for
long-term therapy in bipolar disorder patients.
Lurasidone treatment was associated with a small increase in
prolactin that was not considered to be clinically relevant, as was
found in the previous monotherapy study.20 No new safety concerns
or risks were apparent for lurasidone in the present study, suggesting
that lurasidone is safe and well tolerated across various ethnic
populations.
Olanzapine and quetiapine XR other than lurasiodne are the only
approved medications for bipolar depression in Japan. With these
medications, two randomized, double-blind placebo-controlled studies
that enrolled Japanese patients have been reported. In a 6-week study
of olanzapine in bipolar I patients, 30% of the treatment sample were
Japanese.45 In an 8-week trial of quetiapine XR, all enrolled patients
were Japanese (n = 431), with 29% of these receiving a bipolar I
depression diagnosis.46 The current 6-week flexible-dose study of
lurasidone for the treatment of bipolar I patients included 34% Japa-
nese patients. All three antipsychotics showed significant antidepres-
sant effect in MADRS total score compared to placebo. Interestingly,
individual MADRS items showing greater improvement may differ
depending on the antipsychotics; that is, efficacy was apparent for
sadness and inner tension with lurasidone (see Table S1), while effi-
cacy regarding reduced sleep and reduced appetite was evident with
olanzapine.45
The safety and tolerability profiles also differ for lurasidone
compared with olanzapine and quetiapine XR. In terms of adverse
events, lurasidone was associated with akathisia and nausea,
olanzapine with somnolence and weight increase,45 and quetiapine
XR with somnolence and thirst.46 In the current study (similar to
results from previous studies20,21,38), lurasidone was not associated
with increases in weight or lipid parameters. The lack of weight gain
may be explained by the receptor binding profile of lurasidone, which
has no appreciable affinity for histamine H1 (IC50, >1000 nM) or
5-HT2C (Ki, 415 nM). Inhibitory activity at these receptors has been
shown to be associated with weight gain.47,48 Both olanzapine and
quetiapine have higher affinity for histamine H1 and 5-HT2C recep-
tors, which have been shown to be associated with glucose intoler-
ance and increased insulin resistance,47,49–51 and both have a known
characteristic to increase weight and elevate lipids.52,53
Although detailed comparisons must be made cautiously given
cross-study differences in trial design and study populations,
lurasidone should be a valuable option for the treatment of bipolar
depression in Japan with a different efficacy/safety profile.
A few limitations of this study should be noted. Patients with
serious psychiatric or medical comorbidities were excluded, as were
patients with bipolar II disorder, and therefore the generalizability of
the current findings to patients with those characteristics is unknown.
The extent to which lurasidone is safe and effective over longer
periods of time in Asian populations (including Japanese patients)
needs further investigation.
In conclusion, this study demonstrated that monotherapy with
lurasidone 20–60 mg/day was efficacious, relative to placebo, in the
treatment of depressive symptoms in patients with bipolar I disorder.
Improvement was also observed in global severity of illness, concom-
itant anxiety, and in functioning. Lurasidone was generally well-toler-
ated, especially at the 20–60-mg/day dose range, with low rates of
discontinuation due to adverse events (3.3%). The higher dose of
80–120 mg/day was less effective and had higher rates of adverse
events. Lurasidone had minimal effects on weight and metabolic
parameters, and was associated with a low risk of switching to mania.
These results are consistent with findings from a previously reported
monotherapy study of lurasidone in bipolar I depression,20 suggesting
that lurasidone 20–60 mg/day is effective and safe to treat bipolar I
depression in diverse ethnic populations, including Japanese.
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